

4th Joint Conference of Taiwan and Japan on Medical Products Regulation

Day 1: 7th December 2016

Venue: Nihonbashi Life Science HUB (Joint session and pharmaceuticals/ Health Insurance session), Nihonbashi Life Science Bldg.10F (Medical devices session)

Joint Session	
08:30-09:00	Registration
09:00-09:30	Opening Remarks
	Mr. Hitoshi Funamachi, Senior Executive Director, Interchange Association, Japan
	Mr. Hou-Chun CHANG, Director, Economic Division, Taipei Economic and Cultural Representative Office in Japan
	Mr. Kazuhiko Mori, Councilor, MHLW
	Dr. Shioh-Ing Wu, Deputy Director-General, TFDA
	Mr. Tadaharu Goto, Director General, JPMA
	Mr. Tung-Mao Su, Standing Director, Taiwan Pharmaceutical Manufacturer's Association
	Mr. Koji Nakao, President, JFMDA
	Mr. Chi-Chung Huang, Chairman, Taiwan Medical and Biotech Industry Association
09:30-09:40	Memorial Photo Taking
09:40-10:40	<u>Regulatory Updates for Medical Products in Japan and Taiwan</u> <u>(Moderator: Mr. Yoshihiko Sano (MHLW))</u>
	(1). Currently regulation amendments and future prospects
	(2). Experience sharing on new medical product regulated
	<ol style="list-style-type: none"> 1. Dr. Toshiyosi Tominaga, Associate Executive Director for International Programs, PMDA (25min) 2. Ms. Chao-Yi Wang, Director, Division of Medicinal Products, TFDA (25min) 3. Q and A (10min)
10:40-10:55	Coffee Break

Parallel Session (Pharmaceuticals)	
10:55-11:55	<p>Moderator: Ms. Chao-Yi Wang (TFDA)</p> <p>WGs Progress Report</p> <ul style="list-style-type: none"> -New drugs Dr. Yi-Chu Lin, Section Chief, Division of Medicinal Products, TFDA (8min) -GCP Dr. Hideaki Ui, Division Director, Office of Non-clinical and Clinical Compliance, PMDA (8min) -OTC drugs Mr. Hung-Jung Lien, Section Chief, Division of Medicinal Products, TFDA (8min) -OTC drugs Mr. Fumihito Takanashi, Assistant Director, Office of International Regulatory Affairs, MHLW (8min) -Generic drugs Mr. Naoyuki Yasuda, Office Director, Office of International Programs, PMDA (8min) <p>Panel Discussion (20min)</p>
11:55-13:00	Luncheon
13:00-13:50	<p>Moderator: Mr. Naoyuki Yasuda (PMDA)</p> <p>1. New Strategies and Technologies</p> <p>(1) 3D printing Prof. Jeng-Ywan Jeng, National Taiwan University of Science and Technology (20min)</p> <p>(2) Electronic tools used in safety measures Mr. Atsushi Noguchi, Coordinator, Office of Medical Informatics and Epidemiology, PMDA (20min)</p> <p>Panel Discussion (10min)</p>
13: 50-15:05	<p>Moderator: Dr. Churn-Shiouh Gau (CDE)</p> <p>2. Experience Sharing on maintaining safety and quality of pharmaceuticals</p> <p>(1) Regulatory perspective</p> <ul style="list-style-type: none"> - API regulation and post-approval change: Current management in Taiwan

	<p>Mr. Heng-Jung Lien, Section Chief, Division of Medicinal Products, TFDA (15min)</p> <p>Description and comparison of the demanded document of API for the application of registration of generic medicine</p> <p>Mr. Ryosuke Kuribayashi, Chief Reviewer, Office of Generic Drugs, PMDA (15min)</p> <p>Consideration point of post-approval change</p> <p>Mr. Gou Yamamoto, Deputy Director, Pharmaceutical Evaluation Division, MHLW (15min)</p> <p>(2) Industry perspective</p> <p>Post-approval change application</p> <p>Dr. Alice Hsu, Standard Chemical & Pharmaceutical Co, TW (10min)</p> <p>Post-approval change application</p> <p>Mr. Tomonori Nakagawa, Asia Project Leader, GMP Sub Committee, Quality & Technology Committee, JPMA (10min)</p> <p>Panel Discussion (10min)</p>
15:05-15:20	Coffee Break
15:20-16:20	<p>Moderator: Mr. Yoshihiko Sano (MHLW)</p> <p>3. Post-marketing Management</p> <p>(1) Safety information (including vaccine) report and research in Japan</p> <p>Dr. Daisaku Sato, Division Director, Safety Division, MHLW (15min)</p> <p>(2) Adverse Event Reporting</p> <p>Current Status and policy direction on "Adverse Event Reporting"</p> <p>Ms. Wen-Wen Chen, CEO, Taiwan Drug Relief Foundation (15min)</p> <p>Current Status and policy direction on "Adverse Event Reporting"</p> <p>Ms. Mariko Tsukuda, Reviewer, Office of Safety I, PMDA (15min)</p> <p>Panel Discussion (15min)</p>
Parallel Session (Health Insurance)	
16:20-17:20	<p>Moderator: Mr. Yoshihiko Sano (MHLW)</p> <p>Update on regulations in NHI pricing and related policy</p> <p>-Current update in NHI policy and future directions</p> <p>Mr. Hiroaki Mamiya, Section Chief, Pharmaceutical Affairs Division, MHLW (20min)</p> <p>-Current update in NHI policy and future directions</p> <p>Mr. Chang-Jr Chen, Specialist, Division of Medical Review and Pharmaceutical Benefits, NHIA (20min)</p>

	Panel discussion (20min)
Pharmaceuticals & Health Insurance	
17:20-17:30	Closing Remarks - Ms. Chao-Yi Wang, Director, Division of Medicinal Products, TFDA - Dr. Toshiyoshi Tominaga, Associate Executive Director, PMDA
18:00-	Welcome Reception (JPMA Bldg. 10F)
Parallel Session (Medical Devices)	
11:15-12:25	Moderator: Ms. Yumiko Aoyagi (both session 1&2) (MHLW) 1. Progress of Product Registration WG - Dr. Ta-Jen Wu, Technical Specialist, Division of Medical Devices and Cosmetics, TFDA (20min) Panel Discussion (15min)
	2. Progress of QSD/QMS WG - Mr. Katsuya Sawadaishi, Inspector, Division of Medical Devices, Office of Manufacturing/ Quality and Compliance, PMDA (15min) Panel Discussion (20min)
12:25-13:45	Luncheon
13:45-15:30	Moderator: Mr. Ming-Shin Lee, Director, Division of Risk Management, (Taiwan FDA) 3. Information sharing on recent topics - Software validation Mr. Tzu-Wei Li, Industrial Technology Research Institute of Taiwan (20min) Mr. Keiichiro Ozawa, FUJIFILM Corporation (20min) - In Vitro Companion Diagnostic Devices Mr. Tzu-Wei Li, Industrial Technology Research Institute of Taiwan (20min) Ms. Yumiko Aoyagi, Deputy Director, Medical Device Evaluation Division, MHLW (20min) Panel Discussion (25min)
15:30-15:40	Closing Remarks - Ms. Yu-Roo Chu, Deputy Director, Division of Medical Devices and Cosmetics, TFDA - Dr. Jun Kitahara, Division Director, Office of International Programs, PMDA

15:40-16:00	Coffee Break
16:00-17:30	Closed Meeting 1. Product Registration WG closed meeting 2. QSD/ QMS WG closed meeting
18:00~	Welcome Reception (JPMA Bldg. 10F)